JP2022513098A5 - - Google Patents

Info

Publication number
JP2022513098A5
JP2022513098A5 JP2021527918A JP2021527918A JP2022513098A5 JP 2022513098 A5 JP2022513098 A5 JP 2022513098A5 JP 2021527918 A JP2021527918 A JP 2021527918A JP 2021527918 A JP2021527918 A JP 2021527918A JP 2022513098 A5 JP2022513098 A5 JP 2022513098A5
Authority
JP
Japan
Prior art keywords
composition
administered
fusion protein
composition according
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021527918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059945 external-priority patent/WO2020104948A1/en
Publication of JP2022513098A publication Critical patent/JP2022513098A/ja
Publication of JP2022513098A5 publication Critical patent/JP2022513098A5/ja
Priority to JP2025019347A priority Critical patent/JP2025081388A/ja
Withdrawn legal-status Critical Current

Links

JP2021527918A 2018-11-20 2019-11-19 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 Withdrawn JP2022513098A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019347A JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769675P 2018-11-20 2018-11-20
US62/769,675 2018-11-20
PCT/IB2019/059945 WO2020104948A1 (en) 2018-11-20 2019-11-19 Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019347A Division JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法

Publications (2)

Publication Number Publication Date
JP2022513098A JP2022513098A (ja) 2022-02-07
JP2022513098A5 true JP2022513098A5 (enExample) 2022-11-25

Family

ID=70773869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527918A Withdrawn JP2022513098A (ja) 2018-11-20 2019-11-19 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法
JP2025019347A Pending JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019347A Pending JP2025081388A (ja) 2018-11-20 2025-02-07 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法

Country Status (15)

Country Link
US (2) US20220315633A1 (enExample)
EP (1) EP3883960A4 (enExample)
JP (2) JP2022513098A (enExample)
KR (1) KR20210094584A (enExample)
CN (2) CN113474363A (enExample)
AU (2) AU2019383019A1 (enExample)
BR (1) BR112021009225A2 (enExample)
CA (1) CA3120236A1 (enExample)
EA (1) EA202191424A1 (enExample)
IL (1) IL283189A (enExample)
JO (1) JOP20210111A1 (enExample)
MX (1) MX2021005908A (enExample)
PH (1) PH12021551119A1 (enExample)
SG (1) SG11202104952PA (enExample)
WO (1) WO2020104948A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9131966B2 (en) * 2013-03-11 2015-09-15 DePuy Synthes Products, Inc. Vertebral manipulation assembly
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US20190000923A1 (en) * 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MY205905A (en) * 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Similar Documents

Publication Publication Date Title
Farci et al. Current and future management of chronic hepatitis D
Stanislaus et al. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
JP2019065028A5 (enExample)
DK2694087T3 (en) The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
Deterding et al. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
JP2013543501A5 (enExample)
JP2014114288A5 (enExample)
Gajofatto Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2016516016A5 (enExample)
JP2010529026A5 (enExample)
JP2024531151A5 (enExample)
JPH04504570A (ja) Ｈｉｖ―感染による疾病の治療
JP2006508039A5 (enExample)
JP2015172060A5 (enExample)
KR20160133479A (ko) 자가면역 질환의 치료를 위한 조합 요법
KR20110053327A (ko) 텔라프레비르 투여 방식
JP2017519762A5 (enExample)
Wedemeyer et al. 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31
JP2021004249A5 (enExample)
JP2022514561A5 (enExample)
Bridel et al. Update on multiple sclerosis treatments
Arnason Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis
Masetti et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction.